Fierce Pharma September 11, 2024
Just two years into its existence, radioisotope producer PanTera has drawn 93 million euros ($102.5 million) in an oversubscribed Series A investment round, led by EQT Life Sciences.
It is the largest Series A round ever for a Belgian company in the life sciences sector, according to EQT, and is evidence of the booming interest in radiopharmaceuticals for their ability to precisely target cancer cells.
While there are many small-scale producers of radioisotopes, PanTera has established its niche by developing a patented production method that allows it to potentially become a large-scale producer of actinium-225 (225-Ac), which is the key ingredient needed to manufacture targeted alpha therapies.
The investment will largely support the construction of a new manufacturing...
Today's Sponsors
Today's Sponsor